Neuroprotective Effect of Famotidine in Mouse Models of Alzheimer's Disease

被引:0
|
作者
Sadiq, Mariam H. [1 ]
Al-Zubaidy, Adeeb A. [2 ]
机构
[1] Al Nahrain Univ, Coll Med, Dept Pharmacol, St 60, Baghdad, Iraq
[2] Univ Warith Al Anbiyaa, Coll Med, Dept Pharmacol, Karbala, Iraq
关键词
Alzheimer's disease; famotidine; donepezil; inflammatory cytokines; oxidative stress; COGNITIVE IMPAIRMENT; REPERFUSION INJURY; SCOPOLAMINE; DEFICITS; MEMORY; SCHIZOPHRENIA; MICE;
D O I
10.7754/Clin.Lab.2024.240147
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background: Famotidine is a competitive histamine H-receptor antagonist that reduces the formation of stomach acid and is used to treat gastrointestinal disorders associated with acid reflux, gastroesophageal reflux disease, duodenal ulcer, gastric ulcer, and pathological hypersecretory disorders. This study is designed to investigate the possible neuroprotective effects of the ranolazine scopolamine-induced Alzheimer's disease-like feature in a mouse model. Methods: Mice were divided equally into five groups (ten mice per group), including control group and induction group. The mice in the induction group were administered scopolamine 1 mg/kg i.p., once daily for 7 days, to induce features similar to Alzheimer's disease. The mice in the remaining three treatment groups were given tested medications prophylactically for 14 days. After that the induction was carried out with scopolamine 1 mg/kg i.p., once daily, while the tested medication dosages were continued for an additional 7 days. These treatment groups included: the donepezil group (5 mg/kg/day), the famotidine group (40 mg/kg/day) and the combined group with donepezil (5 mg/kg/day) and famotidine (40 mg/kg/day); all were administrated i.p., once daily. Behavioral parameters were assessed, among others with the Y-maze test and novel object recognition test, and the inflammatory cytokines and oxidative stress parameters were assessed as well. Results: Famotidine exhibits significant improvements in behavior and memory, level of oxidative stress parameter, and inflammatory cytokines. Conclusions: Famotidine and its combination at prescribed doses in the current study improved learning and memory impairments in mice model of Alzheimer's disease probably via their antioxidant and anti-inflammatory properties confirmed by a significant increase in antioxidant mediator and a significant decrease in oxidative stress marker and inflammatory cytokines. (Clin. Lab. 2024;70:1483-1489. DOI: 10.7754/Clin.Lab.2024.240147
引用
收藏
页码:1483 / 1489
页数:7
相关论文
共 50 条
  • [21] Neurogenesis in mouse models of Alzheimer's disease
    Chuang, Tsu Tshen
    BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, 2010, 1802 (10): : 872 - 880
  • [22] Neuroimaging of Mouse Models of Alzheimer's Disease
    Jullienne, Amandine
    Trinh, Michelle V.
    Obenaus, Andre
    BIOMEDICINES, 2022, 10 (02)
  • [23] Transgenic mouse models of Alzheimer's disease
    Sirinathsinghji, DJS
    BIOCHEMICAL SOCIETY TRANSACTIONS, 1998, 26 (03) : 504 - 508
  • [24] Updates on mouse models of Alzheimer’s disease
    Michael Z. Zhong
    Thomas Peng
    Mariana Lemos Duarte
    Minghui Wang
    Dongming Cai
    Molecular Neurodegeneration, 19
  • [25] Transgenic Mouse Models of Alzheimer's Disease
    Elder, Gregory A.
    Sosa, Miguel A. Gama
    De Gasperi, Rita
    MOUNT SINAI JOURNAL OF MEDICINE, 2010, 77 (01): : 69 - 81
  • [26] Transgenic mouse models of Alzheimer's disease
    Janus, C
    Westaway, D
    PHYSIOLOGY & BEHAVIOR, 2001, 73 (05) : 873 - 886
  • [27] Neuroprotective effect of formononetin in ameliorating learning and memory impairment in mouse model of Alzheimer's disease
    Fei, Hong-Xin
    Zhang, Ying-Bo
    Liu, Ting
    Zhang, Xiao-Jie
    Wu, Shu-Liang
    BIOSCIENCE BIOTECHNOLOGY AND BIOCHEMISTRY, 2018, 82 (01) : 57 - 64
  • [28] Motor impairment in Alzheimer's disease and transgenic Alzheimer's disease mouse models
    Wirths, O.
    Bayer, T. A.
    GENES BRAIN AND BEHAVIOR, 2008, 7 : 1 - 5
  • [29] Neuroprotective effects of salidroside administration in a mouse model of Alzheimer's disease
    Li, Qingyun
    Wang, Jinhua
    Li, Yuwang
    Xu, Xiaolin
    MOLECULAR MEDICINE REPORTS, 2018, 17 (05) : 7287 - 7292
  • [30] Neuroprotective effects of fingolimod in mouse models of Parkinson's disease
    Zhao, Peng
    Yang, Xiaoxia
    Yang, Liu
    Li, Minshu
    Wood, Kristofer
    Liu, Qiang
    Zhu, Xiaodong
    FASEB JOURNAL, 2017, 31 (01): : 172 - 179